These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

56 related articles for article (PubMed ID: 7572417)

  • 41. Tissue expression of human decay accelerating factor, a regulator of complement activation expressed in mice: a potential approach to inhibition of hyperacute xenograft rejection.
    Cary N; Moody J; Yannoutsos N; Wallwork J; White D
    Transplant Proc; 1993 Feb; 25(1 Pt 1):400-1. PubMed ID: 7679815
    [No Abstract]   [Full Text] [Related]  

  • 42. Characterization of a CD46 transgenic pig and protection of transgenic kidneys against hyperacute rejection in non-immunosuppressed baboons.
    Loveland BE; Milland J; Kyriakou P; Thorley BR; Christiansen D; Lanteri MB; Regensburg M; Duffield M; French AJ; Williams L; Baker L; Brandon MR; Xing PX; Kahn D; McKenzie IF
    Xenotransplantation; 2004 Mar; 11(2):171-83. PubMed ID: 14962279
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Possibility of prevention of hyperacute rejection by DAF and CD59 in xenotransplantation.
    Miyagawa S; Shirakura R; Matsumiya G; Nakata S; Matsuda H; Hatanaka M; Matsumoto M; Seya T
    Transplant Proc; 1994 Jun; 26(3):1235-8. PubMed ID: 7518114
    [No Abstract]   [Full Text] [Related]  

  • 44. The control of hyperacute rejection by genetic engineering of the donor species.
    White DJ; Cozzi E; Langford G; Oglesby T; Wang MW; Wright L; Wallwork J
    Eye (Lond); 1995; 9 ( Pt 2)():185-9. PubMed ID: 7556715
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Studies on transfer of primate membrane-associated complement inhibitors from recipient blood to porcine donor organs.
    Kroshus TJ; Bolman RM; Dalmasso AP
    Transplant Proc; 1996 Apr; 28(2):601-2. PubMed ID: 8623295
    [No Abstract]   [Full Text] [Related]  

  • 46. Genetic engineering of the donor species to control hyperacute xenograft rejection.
    White DJ; Cozzi E; Langford G; Oglesby T; Wang MW; Wright L; Wallwork J
    Adv Nephrol Necker Hosp; 1995; 24():331-40. PubMed ID: 7572417
    [No Abstract]   [Full Text] [Related]  

  • 47. Complement regulatory molecules: application to therapy and transplantation.
    Morgan BP
    Immunol Today; 1995 Jun; 16(6):257-9. PubMed ID: 7544975
    [No Abstract]   [Full Text] [Related]  

  • 48. Hyperacute rejection models: ex vivo xenoperfusion systems.
    Grinyo JM; Cruzado JM; Torras J
    Transplant Proc; 1999; 31(1-2):970-1. PubMed ID: 10083432
    [No Abstract]   [Full Text] [Related]  

  • 49.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 50.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 51.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 52.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 53.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 54.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 55.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 56.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]     [New Search]
    of 3.